| Literature DB >> 31020199 |
Stefano Lanzi1, Luca Calanca1, Amélie Borgeat Kaeser2, Lucia Mazzolai1.
Abstract
BACKGROUND: Takayasu arteritis (TAK) is a rare chronic inflammatory vasculitis predominantly affecting the aorta and its main branches. Takayasu arteritis has been shown to increase cardiovascular risk. Supervised exercise training (SET) is a well-recognized and effective therapeutic tool improving walking performances in patients with chronic atherosclerotic disease; however, the effects of SET, and the underlying mechanisms, remain poorly documented in TAK patients. CASEEntities:
Keywords: Case report; Exercise; Intermittent claudication; Muscle oxygenation; Near-infrared spectroscopy; Takayasu; Vascular rehabilitation
Year: 2018 PMID: 31020199 PMCID: PMC6426037 DOI: 10.1093/ehjcr/yty123
Source DB: PubMed Journal: Eur Heart J Case Rep ISSN: 2514-2119
Figure 1Computed tomography angiography (maximum intensity projection 3D reconstruction) showing multiple stenoses/occlusions of iliac and femoral arteries.
Walking performances and physical function of lower extremities before and after the supervised exercise training programme
| Variables | Before | After | Change (%) |
|---|---|---|---|
| Walking performance | |||
| PFWD (m) | 90.0 | 110.0 | +22 |
| MWD (m) | 150.0 | 560.0 | +273 |
| 6MWD (m) | 352.0 | 585.0 | +66 |
| Resting time during 6MWT (s) | 110 | 0 | |
| 6MWTvas | 6.2 | 2.0 | −68 |
| SPPB | |||
| Stand test summed (s) | 30.0 | 30.0 | 0 |
| 4-m velocity test (m s−1) | 1.1 | 1.6 | +43 |
| 5× chair stand test (s) | 14.0 | 5.9 | −58 |
| SPPB total score | 10.0 | 12.0 | +20 |
| SCT (s) | 5.5 | 3.1 | −43 |
MWD, maximal walking distance; 6MWD, six-minute walking distance; 6MWTvas, visual analogical scale at the end of the 6-min walking test; PFWD, pain-free walking distance; SCT, stair climbing test; SPPB, short physical performance battery.
Figure 2Calf muscle oxygen saturation (StO2) (A) and delta StO2 (ΔStO2) (B) at rest (StO2R), during the first 2 minutes of effort and at the pain-free walking distance (PFWD) and maximal walking distance (MWD). StO2R was recorded after 3 min of standing before exercise. Each time point was calculated as the average StO2 during the last 15 s and ΔStO2 was calculated as the StO2 at each time point minus the baseline StO2.
Summary of studies
| References | Arteritis | Gender | Age | BMI | Exercise training | Main findings | |
|---|---|---|---|---|---|---|---|
| Lima | Arteritis with no identifiable cause | 1 | Male | 33 | 29.4 | 16-week unsupervised ET Patient were instructed to walk 1 h/day until maximum claudication pain at least five times per week Weekly phone to monitor training adherence | ↑ in claudication distance and total walking distance during treadmill and 6-min walking test ↑ in QoL (assessed with SF-36) ↓ SBP, DBP, rate pressure product, and LF/HF ratio |
| Oliveira | TAK | 6 | Female | 35.3 ± 6.6 | 26.6 ± 4.6 | 12-week SET (2×/week) 30–50 min (gradually increased) of treadmill walking HR between the VT and RCP was used to determine exercise intensity during the training sessions | ↑ muscle strength and physical function ↑ time to reach VT = V’O2peak, time-to-exhaustion = endothelial function = QoL (assessed with SF-36 and HAQ) ↓ TNF ↑ VEGF and PDGF AA |
DBP, diastolic blood pressure; HAQ, Health Assessment Questionnaire; HR, heart rate; LF/HF ratio, ratio of the low- and high-frequency bands in heart rate variability; PDGF AA, platelet-derived growth factor; QoL, quality of life; RCP, respiratory compensation point; SBP, systolic blood pressure; SET, supervised exercise training; SF-36, medical Outcome Study Short-Form 36 General Health Survey; TAK, Takayasu arteritis; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor; V’O2peak, peak oxygen uptake; VT, ventilatory threshold; ↑, increase; ↓, decrease; =, similar.
| Time | Events |
|---|---|
| Between 18 and 16 months prior to supervised exercise training (SET) |
Diagnosis of TAK CRP = 292 mg L−1 Lower limb claudication: 50 m Treatment: i.v. corticosteroid therapy, Prednisone 45 mg day−1 (1 mg kg day−1) and Methotrexate 10 mg week−1 |
| Between 16 and 12 months prior to SET |
Lower limb claudication: 200 m CRP = 1 mg L−1 Treatment: Methotrexate 10 mg week−1; Prednisone decrease until 17.5 mg day−1 |
| Between 12 and 11 months prior to SET |
Abdominal pain CRP = 91 mg L−1 Treatment: Prednisone 40 mg day−1 and Tocilizumab 8 mg kg month−1, Methotrexate was stopped |
| Between 11 and 7 months prior to SET |
Lower limb claudication: 200 m No significant sign of inflammation CRP = 1 mg L−1 Treatment: Prednisone decrease until 10 mg day−1, Tocilizumab 8 mg kg month−1 |
| Between 4 months to the beginning of SET |
Lower limb claudication: 200 m No significant sign of inflammation CRP = 1 mg L−1 Treatment: Prednisone decreases until 5 mg day−1, Tocilizumab 8 mg kg month−1 SET was initiated |
| Following SET |
Significant improvement in walking performances and physical function No significant sign of inflammation CRP <1 mg L−1 |